Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 651 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Three Women Running the Length of Michigan to Raise Funds for... February 4, 2022 Satisfying Snacks November 13, 2020 Analysis of the Gut Microbiome Provides Clues to Survival Following Nivolumab... July 9, 2021 Pancancer Activity of Dabrafenib Plus Trametinib in Patients with BRAFV600E-Mutated Rare... April 24, 2023 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Equidacent Clinics Offering “Mammoglam” Services to Encourage More Women to Get Mammograms Can we grow the treatments of tomorrow? – That Cancer Conversation Cancer in My Community: The Role of Cancer Screening in Guatemala
